Epizyme, Inc. (NASDAQ:EPZM) Q4 2018 Earnings Conference Call - Final Transcript
Feb 26, 2019 • 08:30 am ET
Hello, and welcome to Epizyme's Fourth Quarter and Full Year 2018 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. Please be advised this call is being recorded at Epizyme's request.
I would now like to turn the call over to Alicia Davis. You may begin.
Thank you, Kevin, and good morning. On the call with me today are our CEO, Rob Bazemore; Dr. Shefali Agarwal, Chief Medical Officer; and Matt Ros, our Chief Strategy and Business Officer.
Today's discussion will include forward-looking statements related to Epizyme's current plans and expectations, which are subject to risks and uncertainties. Actual results may differ materially due to various important factors including those described in the Risk Factor section of our most recent Form 10-K and other SEC filings. These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.
Now, let me turn the call over to Rob. Rob?
Robert B. Bazemore
Thank you, Alicia, and good morning, everyone. Across all aspects of our business at Epizyme, we have made great progress toward our mission of rewriting the treatment of cancer and other serious diseases through the development of novel, epigenetic medicines. We are pioneers in this area, exemplified by our progress with tazemetostat, our first-in-class oral EZH2 inhibitor, and we are excited to highlight for you today some of the exciting developments that we've made in the last year.
2018 was a year of many important milestones, and we continue to successfully execute on our Vision 2020, comprised of four ambitious goals. Those are to launch tazemetostat in both solid tumors and non-Hodgkin lymphoma; expand tazemetostat's benefit into earlier lines of treatment, combinations and additional tumor types; build a robust clinical pipeline with at least three new product candidates in development; and further establish our leadership in epigenetics.
As we look ahead, 2019 is poised to be the most transformational year for the Company yet. We stand well positioned to deliver on our Vision 2020 and to enhance the value of Epizyme in the short, mid, and long term. The most near-term opportunities are through the initial launches of tazemetostat for epithelioid sarcoma and follicular lymphoma, if approved.
Mid-term growth will come through significant expansion of our tazemetostat program into earlier lines of treatment in FL and new indications as a combination agent. Longer term, we're planning for additional value creation through the advancement of new assets, including EZM8266 and our earlier partner programs with Boehringer Ingelheim.
With tremendous progress made across all aspects of our business, I am confident in the future of Epizyme. Our team is hard at work preparing for the submission of two successive NDAs in 2019, an opportunity that few companies get, but one for which we are well prepared. We're on track to submit our first NDA for accelerated approval of tazemetostat for